ATE359086T1 - Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen - Google Patents

Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen

Info

Publication number
ATE359086T1
ATE359086T1 AT03007342T AT03007342T ATE359086T1 AT E359086 T1 ATE359086 T1 AT E359086T1 AT 03007342 T AT03007342 T AT 03007342T AT 03007342 T AT03007342 T AT 03007342T AT E359086 T1 ATE359086 T1 AT E359086T1
Authority
AT
Austria
Prior art keywords
progression
inhibiting
neuropathic pain
achieveing
analgesia
Prior art date
Application number
AT03007342T
Other languages
German (de)
English (en)
Inventor
Ramasharma Kristipati
Peter Isadore Adriaenssens
Stephen Scott Bowersox
Theresa Gadbois
Robert R Luther
Gary Arthur Amstutz
Mark Raymond Pettus
Kishochandra Gohil
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/496,847 external-priority patent/US5795864A/en
Priority claimed from US08/613,400 external-priority patent/US6054429A/en
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of ATE359086T1 publication Critical patent/ATE359086T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Control Of El Displays (AREA)
  • Saccharide Compounds (AREA)
AT03007342T 1995-06-27 1996-06-26 Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen ATE359086T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/496,847 US5795864A (en) 1995-06-27 1995-06-27 Stable omega conopetide formulations
US08/613,400 US6054429A (en) 1996-03-08 1996-03-08 Epidural method of producing analgesia

Publications (1)

Publication Number Publication Date
ATE359086T1 true ATE359086T1 (de) 2007-05-15

Family

ID=27052304

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03007342T ATE359086T1 (de) 1995-06-27 1996-06-26 Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen
AT96923511T ATE235914T1 (de) 1995-06-27 1996-06-26 Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT96923511T ATE235914T1 (de) 1995-06-27 1996-06-26 Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen

Country Status (13)

Country Link
EP (2) EP1336409B1 (enExample)
JP (1) JP2838073B2 (enExample)
AT (2) ATE359086T1 (enExample)
AU (1) AU695166B2 (enExample)
CA (1) CA2224795C (enExample)
DE (3) DE69637021T2 (enExample)
DK (2) DK0835126T3 (enExample)
ES (2) ES2194998T3 (enExample)
FR (1) FR05C0027I2 (enExample)
LU (1) LU91181I2 (enExample)
NL (1) NL300201I2 (enExample)
PT (2) PT1336409E (enExample)
WO (1) WO1997001351A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5931809A (en) * 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
CA2319038A1 (en) * 1998-02-20 1999-08-26 Zeneca Limited Analgesic peptides from venom of grammostola spatulata and use thereof
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
EP2412719A1 (en) 2002-12-02 2012-02-01 Xenome Ltd Chi-conotoxin peptides
WO2004050690A1 (en) 2002-12-02 2004-06-17 Xenome Ltd NOVEL χ-CONOTOXIN PEPTIDES (-I)
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1911763B1 (en) 2003-01-28 2010-08-11 Ironwood Pharmaceuticals, Inc. Compositions for the treatment of gastrointestinal disorders
CA2540895C (en) 2003-10-02 2016-08-02 Elan Pharmaceuticals, Inc. Combinations of ziconotide and opioids for reducing pain
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
US8188048B2 (en) 2006-06-23 2012-05-29 Xenome Limited Combination therapy
JP2010509209A (ja) * 2006-11-04 2010-03-25 エニジェン カンパニー リミテッド 新規なω−コノトキシン
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2300044A4 (en) * 2008-05-06 2012-04-18 Relevare Aust Pty Ltd METHOD AND COMPOSITIONS FOR TREATING PAIN WITH OMEGA CONOTOXINES
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20100221329A1 (en) 2008-12-03 2010-09-02 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
MX381407B (es) 2008-12-31 2025-03-12 Ardelyx Inc Compuestos y métodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrógeno (nhe) en el tratamiento de trastornos asociados con retención de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
HRP20191000T1 (hr) 2013-04-12 2019-09-20 Ardelyx, Inc. Spojevi za vezanje nhe3 i metode inhibiranja transporta fosfata
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
MX2019008171A (es) 2017-01-09 2020-02-05 Ardelyx Inc Inhibidores del antiporte mediado por nhe.
MX395405B (es) 2017-01-09 2025-03-25 Ardelyx Inc Compuestos útiles para tratar trastornos del tracto gastrointestinal.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3926287A1 (de) * 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
AU3074592A (en) * 1991-11-12 1993-06-15 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage
WO1993013128A1 (en) * 1991-12-30 1993-07-08 Neurex Corporation Methods of producing analgesia and enhancing opiate analgesia
JPH06247879A (ja) * 1993-02-17 1994-09-06 Bristol Myers Squibb Co デオキシチミジンヌクレオシドを含有する注射用製剤の安定化方法およびその方法によって得られる安定化注射用製剤

Also Published As

Publication number Publication date
CA2224795A1 (en) 1997-01-16
WO1997001351A1 (en) 1997-01-16
AU695166B2 (en) 1998-08-06
FR05C0027I2 (enExample) 2006-12-29
PT835126E (pt) 2003-07-31
DK0835126T3 (da) 2003-07-14
EP0835126B1 (en) 2003-04-02
FR05C0027I1 (enExample) 2005-08-12
JP2838073B2 (ja) 1998-12-16
AU6400296A (en) 1997-01-30
NL300201I1 (nl) 2005-09-01
EP0835126A1 (en) 1998-04-15
HK1058146A1 (en) 2004-05-07
DE69637021D1 (de) 2007-05-24
NL300201I2 (nl) 2006-02-01
ATE235914T1 (de) 2003-04-15
LU91181I2 (fr) 2005-09-06
DE122005000043I2 (de) 2006-08-03
EP1336409B1 (en) 2007-04-11
CA2224795C (en) 2001-04-03
DE69627153T2 (de) 2003-12-04
ES2194998T3 (es) 2003-12-01
DE69627153D1 (de) 2003-05-08
JPH09104634A (ja) 1997-04-22
ES2283671T3 (es) 2007-11-01
DK1336409T3 (da) 2007-08-13
EP1336409A1 (en) 2003-08-20
DE69637021T2 (de) 2008-01-10
DE122005000043I1 (de) 2006-06-29
PT1336409E (pt) 2007-06-29

Similar Documents

Publication Publication Date Title
ATE359086T1 (de) Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen
ES2052871T3 (es) Preparacion de bis (3,5-di-t-butil-4-hidroxifeniltio)metano.
HU9701059D0 (en) Use of strontium salts for the production of pharmaceutical compositions intended for the treatment of arthrosis
MY131458A (en) Pyrolopyrimidine compounds
MX9709915A (es) Heterociclos de peptidilo y composiciones que los contienen, utiles en el tratamiento de trastornos relacionados con trombina, y uso de los mismos.
DE69117117D1 (de) Reinigungszusammensetzung zur Vorbeugung und Milderung von Hautreizungen
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
ATE330554T1 (de) Enossales einzelzahnimplantat
DE69601041D1 (de) Vorrichtung zur Gewinnung von Sauerstoff
DE69309763D1 (de) Vorrichtung zur Herstellung von Rohren
EP0735870A4 (en) Use of pla 2? inhibitors as treatment for alzheimer's disease
DE69601295D1 (de) Vorrichtung zur Gewinnung von Sauerstoff
ATE206913T1 (de) Nasale und okulare anwendung von ketamin zur schmerzbeherrschung und entgiftung
DE69429023D1 (de) Vorrichtung zur Herstellung von Stempeln
DE59309089D1 (de) Lichtempfindliches Gemisch zur Herstellung von Relief- und Druckformen
ZA981780B (en) The use of levobupivacaine in paediatric surgery
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DK0743060T3 (da) Anvendelse af tandplejemidler indeholdende bovint colostrum
DE59600130D1 (de) Vorrichtung zur Versorgung von Knochenbrüchen
DE59408857D1 (de) Vorrichtung zur kontinuierlichen Herstellung von Polyacetalen und ihre Verwendung
DE69316498D1 (de) Vorrichtung zur Herstellung von Schablonen
GR3029489T3 (en) Use of leflunomid for the inhibition of interleukin 8.
DE69402105D1 (de) Vorrichtung zur Herstellung von Elektreten
FR2710539B1 (fr) Ensemble d'aiguille chirurgicale.
DE69720064D1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1336409

Country of ref document: EP